Financial Review: Spectral AI (NASDAQ:MDAI) and Competitive Technologies (OTCMKTS:CTTC)

Competitive Technologies (OTCMKTS:CTTC) and Spectral AI (NASDAQ:MDAI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Profitability

This table compares Competitive Technologies and Spectral AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Competitive Technologies	N/A	N/A	N/A
Spectral AI	-51.97%	N/A	-8.69%

Valuation and Earnings

This table compares Competitive Technologies and Spectral AI”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Competitive Technologies	N/A	N/A	N/A	N/A	N/A
Spectral AI	$29.58 million	1.64	-$15.31 million	($0.69)	-2.64

Competitive Technologies has higher earnings, but lower revenue than Spectral AI.

Analyst Ratings

This is a summary of current ratings and recommmendations for Competitive Technologies and Spectral AI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Competitive Technologies	0	0	0	0	0.00
Spectral AI	0	0	1	0	3.00

Spectral AI has a consensus price target of $3.50, indicating a potential upside of 92.31%. Given Spectral AI’s stronger consensus rating and higher possible upside, analysts clearly believe Spectral AI is more favorable than Competitive Technologies.

Insider and Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. 17.5% of Competitive Technologies shares are owned by insiders. Comparatively, 30.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Spectral AI beats Competitive Technologies on 6 of the 8 factors compared between the two stocks.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.